Euromedia24 on Play Store Euromedia24 on App Sore
BNB

$870.47

BTC

$113082

ADA

$0.868816

ETH

$4608.63

SOL

$213.76

31 °

Yerevan

20 °

Moscow

45 °

Dubai

20 °

London

26 °

Beijing

23 °

Brussels

16 °

Rome

23 °

Madrid

BNB

$870.47

BTC

$113082

ADA

$0.868816

ETH

$4608.63

SOL

$213.76

31 °

Yerevan

20 °

Moscow

45 °

Dubai

20 °

London

26 °

Beijing

23 °

Brussels

16 °

Rome

23 °

Madrid

Drug named to reduce risk of death from aggressive prostate cancer by 40%


Men with recurrent prostate cancer after surgery or radiation therapy have a new option. a clinical trial showed that adding enzalutamide to standard hormone therapy reduced the risk of death by 40%. The study was published in the New England Journal of Medicine (NEJM).

"After initial treatment, some patients develop aggressive and rapidly spreading disease," explained study leader Steven Friedland, professor of urology and director of the Center for Integrative Cancer and Lifestyle Research at Cedars-Sinai Cancer. "The hormone therapy we've been using for 30 years has not improved survival rates. So these results are a real breakthrough."

The study involved more than 1,000 patients from 17 countries, all diagnosed with high-risk recurrent prostate cancer, a form of the disease in which PSA (prostate-specific antigen) levels rise sharply after treatment, indicating the likelihood of the tumor recurring and spreading, often to the bones or spine.

The participants were divided into three groups. one received standard hormone therapy, the second enzalutamide alone, and the third a combination of both. After an eight-year follow-up, patients receiving the combination therapy had a 40.3% lower risk of death than those receiving the other treatments.

"These data show that we have finally found a therapy that can prolong the lives of patients with an aggressive form of the disease," said Hyun Kim, MD, chief of the Department of Urology at Cedars-Sinai.

Enzalutamide is already approved and included in the National Complex Cancer Network guidelines. The authors state that these new results will strengthen its status and make the combination the standard of care for recurrent, biochemically active prostate cancer.

"This is one of those discoveries that directly changes clinical practice," emphasized Friedland. "We now have an effective way to improve the prognosis of thousands of men around the world."

Translation by Euromedia24.com

News

What Hrant Tokhatyan Looks Like After a Prolonged Illness (Photo)
The Georgian Government Has Decided to Ban Surrogacy
Thousands Protest in Lisbon Under Torrential Rain Over Price Increases and Housing Crisis (Photos)
People Poisoned by Carbon Monoxide in Church in Germany
Chain Accident Near Yerevan Lake: There Are Casualties and Injuries
Evacuation carried out at Tromsø Airport in Norway: What is known
In Yakutia, a man killed his 15-year-old stepson, injured his 14-year-old son, attacked his wife, and then committed suicide
Details Emerge on the Death of Former Head of Italy’s Police
Snowfall in Vardenis, Martuni, Ashotsk regions
Ara Gevorgyan's "Artsakh" Composition Performed on Georgia's X Factor TV Show (Video)
Two 15-Year-Old Students of Ararat State College Went to Class with a Pistol and a Knife with a Hidden Lock
Vladimir, this is unacceptable. Italy's Prime Minister criticized Zelensky
In Lernavan, a ruling party MP insulted a villager during a campaign; a scuffle ensued, says Ioannisyan
Major fire breaks out at a confectionery factory in Indonesia; there are casualties
Belgium to Close Its Airspace for 14 Hours Due to Strike
In Talin, Police Officers and Two Young Men Rescued a Russian Citizen and Six Family Members from a Fire in a Nissan
Precipitation Expected in the Republic; Air Temperature to Decrease
Final lists published for Local Self-Government elections to be held on November 29
Trees Fell and Roofs Damaged Due to Strong Winds in Gegharkunik and Lori
We highly value strengthening high-level political dialogue with Lebanon: Pashinyan to Salameh